Edward Tung serves as both CEO and General Counsel of MyoMed Bio, a company developing Myoblast Transfer Therapy (MTT), a kind of regenerative medicine, for heart failure, Duchenne Muscular Dystrophy (DMD), and other muscle-related diseases.
In-House Insights: Managing Legal Strategy in Cross-Border Biotech
CEO and General Counsel of MyoMed Bio, explains how legal strategy—spanning IP, regulatory compliance, and cross-border structuring—is essential for enabling clinical development, managing geopolitical and data protection risks, and aligning biotech operations across China, the U.S., and Australia.
By CLP staff